Exosomes vs PRP
A supplied, characterized, allogeneic material against one prepared on site from the recipient's own blood. This is a comparison of supply and standardization, not of clinical outcomes.
Material ComparisonResearch Use Only
What is the difference between exosomes and PRP?
PRP is an autologous preparation made on site by centrifuging the recipient's own blood; MSC-derived exosomes are an allogeneic product manufactured from donated umbilical cord tissue, released against a specification, and shipped ready to use. The practical distinction is where the material is made and what is known about it before it is drawn up.
Akira Biotech does not distribute PRP and makes no claim that either material performs better than the other in any application. Everything below concerns how the two are sourced, documented, and handled.
Side by side
| MSC-derived exosomes | Platelet-rich plasma | |
|---|---|---|
| Origin | Allogeneic — cultured from Wharton's Jelly in donated umbilical cord tissue | Autologous — prepared from the recipient's own blood draw |
| Preparation | Manufactured under cGMP- and ISO-aligned conditions by the partner laboratory, then shipped | Drawn and centrifuged on site immediately before use |
| Dose expression | A counted particle number: 400 billion+ exosomes per mL, NTA-validated per batch | Platelet concentration relative to that individual's baseline, which varies per draw |
| Batch documentation | Certificate of analysis on every batch — particle count, identity markers, sterility | No batch document; the preparation is made per patient |
| Composition | mRNA, miRNA, proteins, and lipids packaged in 40–150 nm vesicles; cargo profile set by the parent lineage | Platelet-derived growth factors, plasma proteins, and residual cellular components |
| Consistency between uses | A specification the batch is released against | Varies with the donor's age, health, haematocrit, and the spin protocol used |
| Chair time | Thaw and draw up — no draw or centrifugation step | Draw, spin, and separate before the material is available |
| Storage | Cryopreserved and shipped cold chain; do not refreeze after thaw | Prepared fresh; not stored |
| Lineage selection | 17 exosome products, each from a different parent lineage | Not applicable — composition follows the donor's blood |
Standardization is the substantive difference
An autologous preparation is defined by the person it came from. A manufactured product is defined by a release specification.
- A number you can put in a protocol. Exosome dose is expressed as particles — 400 billion+ per mL, or 1.2 trillion+ in a 3 mL vial — validated by nanoparticle tracking analysis on every batch.
- A document you can file. Every batch ships with a certificate of analysis recording identity, purity, potency, and safety testing. An autologous preparation has no equivalent.
- A variable removed.Platelet yield varies with the donor's age, health, haematocrit, and the spin protocol; a released batch does not vary between the units drawn from it.
- A choice of lineage. Seventeen exosome products are offered, each carrying the cargo profile of a different parent cell.
Workflow and handling
What changes operationally when a material arrives rather than being prepared.
Exosomes
- Arrives cryopreserved under a temperature-controlled cold chain.
- Requires cold storage on site and a controlled thaw; do not refreeze after thaw.
- No draw and no centrifugation step before use.
- Ordered ahead against a lead time rather than prepared on demand.
PRP
- Requires a draw, a centrifuge, and a validated spin protocol on site.
- No cold storage or shipping logistics.
- Available on demand, with no lead time and no inventory.
- Prepared fresh for each recipient and not stored.
What is not claimed on this page
Both materials appear in published research literature. That literature is not ours, and it is not evidence about Akira Biotech material.
- No efficacy, outcome, or superiority claim is made for exosomes over PRP, or for either material in any indication.
- Akira Biotech supplies laboratory reagents for research use only, not approved by the FDA or any other regulatory authority, and not for use in or on humans.
- Nothing here constitutes medical advice, clinical guidance, or a recommendation to substitute one material for another.
These are experimental use cases, provided as a scientific reference for researchers. Except where noted, they did not use Akira Biotech materials, and results may not be reproducible with ours. Akira Biotech supplies laboratory reagents for research use only. Our products are NOT approved by FDA or any regulatory authority and are not for use in or on humans.
Next steps
Exosome products are supplied by inquiry, with pricing quoted against requirements and order volume.
Need Access to Full Product Information?
Our client portal provides detailed specifications, protocols, certificates of analysis, and streamlined ordering for qualified researchers and healthcare professionals.